Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Provectus announced 12-month outcomes from the 330-patient REAGIR trial, which failed to show a statistically significant difference in primary endpoints between RB-PDAT and sham for infectious keratitis. Despite the primary miss, a pre-specified subgroup analysis of Fusarium patients (63% of enrollees) showed a directionally favorable signal in visual acuity, while Aspergillus patients trended worse. Preclinical data presented at ARVO also demonstrated 74% biofilm inhibition in MRSA and enhanced cysticidal activity with repeat treatment protocols.
Key figures
- Drug Name
- Rose Bengal Sodium (RBS)
- Reagir trial patients
- 330
- Fusarium va diff lines
- 0.17 better
- Aspergillus va diff lines
- 0.39 worse
- Fusarium subgroup percent
- 63
- Biofilm inhibition percent
- 74
- Cysticidal inhibition percent 24h
- 100
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.